Merck (MRK) to Further Streamline R&D Unit; Job Cuts Planned
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $128.06 -1.76%
Revenue Growth %: +3.8%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
DGICA, NEXT, REPL, More
Revenue Growth %: +3.8%
Financial Fact:
Materials and production: 5.59B
Today's EPS Names:
DGICA, NEXT, REPL, More
Join SI Premium – FREE
(Updated - June 14, 2013 1:34 PM EDT)
Merck & Co., Inc. (NYSE: MRK) said to cut jobs and change organizational structure of R&D unit.
According to Dow Jones, a spokesperson commented Friday, "The changes will involve a reduction in force, some more immediate and some over time...These changes are part of our existing strategy and ongoing commitment to streamline our operating model and aggressively manage our cost structure."
Changes will come at Marck Research laboratories (MRI). It wasn't made clear what the new arrangement will be or how many positions will be cut.
Over the last few years, Merck has had some kinks appear in its pipeline. Heart drugs Tredaptive and vorapaxar have had negative study results while the pharma's proposed bone-building drug odanacatib has seen a delay to regulatory filing.
Shares of Merck are up 0.3 percent Friday.
Merck & Co., Inc. (NYSE: MRK) said to cut jobs and change organizational structure of R&D unit.
According to Dow Jones, a spokesperson commented Friday, "The changes will involve a reduction in force, some more immediate and some over time...These changes are part of our existing strategy and ongoing commitment to streamline our operating model and aggressively manage our cost structure."
Changes will come at Marck Research laboratories (MRI). It wasn't made clear what the new arrangement will be or how many positions will be cut.
Over the last few years, Merck has had some kinks appear in its pipeline. Heart drugs Tredaptive and vorapaxar have had negative study results while the pharma's proposed bone-building drug odanacatib has seen a delay to regulatory filing.
Shares of Merck are up 0.3 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- Informa TechTarget posts £165M in H1 2026 revenue, loss narrows
- Merck (MRK) PT Raised to $150 at Barclays
Create E-mail Alert Related Categories
Guidance, Insiders' BlogRelated Entities
LayoffsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
